Autoantibody to von Willebrand factor in systemic lupus erythematosus.
A 17-year old woman (patient 1) was found to have severe bleeding as the initial manifestation of systemic lupus erythematosus. Profound deficiencies of factor VIII coagulation activity (10%), von Willebrand factor (vWF) antigen (< 10%), and ristocetin cofactor (< 1%), and a disproportionate loss of large molecular weight multimers of vWF were observed. An antibody to vWF was suspected, and an enzyme-linked immunoadsorbent assay (ELISA) was devised to detect and quantify such antibody. The ELISA measured the binding of anti-vWF antibody from sample plasma to surface-bound vWF antigen. Binding was detected by a conjugate of alkaline phosphatase with affinity-purified anti-human immunoglobulin G, A, or M and a chromogenic substrate for alkaline phosphatase. Controls included plasma from normal subjects, from patients with von Willebrand's disease, and from a patient (patient 2) with type III von Willebrand's disease who had developed an inhibitor to vWF. Analysis of our patient's plasma revealed immunoglobulin G, A, and M anti-vWF antibodies. Preincubation of the plasma from patient 1 and patient 2 with pure vWF antigen completely inhibited antibody binding, confirming antibody specificity. These antibodies were quantitatively titered by determining the volume ratio of normal pooled plasma (a source of vWF antigen) to test plasma required to inhibit 50% of the antibody binding to immobilized vWF antigen. The value was 0.8 +/- 0.3 (mean +/- SD of three determinations) for the immunoglobulin G of our patient as compared with 15.6 +/- 2.9 for the immunoglobulin G of patient 2. The titers of the immunoglobulin A and M were less than 0.05.(ABSTRACT TRUNCATED AT 250 WORDS)
Soff
G A
GA
Department of Medicine, Northwestern University Medical School, Chicago, Illinois 60611-3008.
Green
D
D
D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis*; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D011241:Prednisone / Q000627:therapeutic use; D014592:Uterine Hemorrhage / Q000209:etiology; D014842:von Willebrand Diseases / Q000150:complications* / Q000188:drug therapy; D014841:von Willebrand Factor / Q000276:immunology*
D001323:Autoantibodies; D007074:Immunoglobulin G; D014841:von Willebrand Factor; D011241:Prednisone